Irsogladine/lafutidine

Drug Profile

Irsogladine/lafutidine

Alternative Names: BRI-1501

Latest Information Update: 15 Feb 2017

Price : $50

At a glance

  • Originator Boryung Pharmaceutical
  • Class Acetamides; Antiulcers; Cytoprotectives; Gastric antisecretories; Neuroprotectants; Piperidines; Pyridines; Small molecules
  • Mechanism of Action Cholinesterase inhibitors; Histamine H2 receptor antagonists; Phosphoric diester hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Gastric ulcer

Most Recent Events

  • 29 Dec 2016 Boryung Pharmaceutical completes a phase I trial in Gastric ulcer (In volunteers) in South Korea (PO) (NCT02759224)
  • 19 May 2016 Chemical information added
  • 01 Apr 2016 Phase-I clinical trials in Gastric ulcer (In volunteers) in South Korea (PO) (NCT02759224)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top